CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | first generation antipsychotic |
|
Accession: | CHEBI:65190
|
browse the term
|
Definition: | Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased. |
Synonyms: | related_synonym: | first generation antipsychotic agent; first generation antipsychotic agents; first generation antipsychotic drug; first generation antipsychotic drugs; first generation antipsychotics; typical antipsychotic; typical antipsychotic agent; typical antipsychotic agents; typical antipsychotic drug; typical antipsychotic drugs; typical antipsychotics |
| xref: | Wikipedia:Typical_antipsychotic |
|
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
Chlorprothixene inhibits the reaction [(2-(2',6'-dimethoxy)phenoxyethylamino)methylbenzo-1,4-dioxane binds to HTR1A protein] |
CTD |
PMID:2891550 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Chlorprothixene results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Prl |
prolactin |
increases secretion |
ISO |
Chlorprothixene results in increased secretion of PRL protein |
CTD |
PMID:10525070 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Ache |
acetylcholinesterase |
increases activity |
ISO |
Acepromazine results in increased activity of ACHE protein |
CTD |
PMID:29614332 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
acetophenazine binds to and results in decreased activity of AR protein |
CTD |
PMID:17606915 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression |
ISO EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB11 mRNA Chlorpromazine results in decreased expression of ABCB11 mRNA; Chlorpromazine results in decreased expression of ABCB11 protein |
CTD |
PMID:27344345 PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression decreases activity |
ISO |
Chlorpromazine analog results in increased expression of ABCB1 mRNA Chlorpromazine results in decreased activity of ABCB1 protein |
CTD |
PMID:15924885 PMID:16810505 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects activity |
EXP |
Chlorpromazine affects the activity of ABCB1B protein |
CTD |
PMID:12626638 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCB4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ABCB6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcb9 |
ATP binding cassette subfamily B member 9 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ABCB9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:32,499,213...32,531,932
Ensembl chr12:32,499,225...32,531,931
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
EXP ISO |
Chlorpromazine results in increased expression of ABCC2 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27765674 PMID:35708773 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions decreases expression |
ISO EXP |
Chlorpromazine analog results in increased expression of ABCC3 mRNA [Bile Acids and Salts co-treated with Chlorpromazine] results in decreased expression of ABCC3 mRNA Chlorpromazine results in decreased expression of ABCC3 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:35708773 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ABCC4 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ABCG8 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
decreases phosphorylation |
EXP |
Chlorpromazine results in decreased phosphorylation of ACACA protein |
CTD |
PMID:17512020 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
decreases activity increases activity multiple interactions |
ISO |
Chlorpromazine results in decreased activity of ACHE protein Chlorpromazine results in increased activity of ACHE protein Dichlorvos promotes the reaction [Chlorpromazine results in decreased activity of ACHE protein] |
CTD |
PMID:4859365 PMID:29614332 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of ADRA1A protein |
CTD |
PMID:23611293 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of ADRA1B protein |
CTD |
PMID:23611293 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Afp |
alpha-fetoprotein |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of AFP mRNA |
CTD |
PMID:15924885 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Agrn |
agrin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of AGRN mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects activity |
EXP |
Chlorpromazine affects the activity of AHR protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak3 |
adenylate kinase 3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of AK3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:226,737,472...226,764,647
Ensembl chr 1:226,739,318...226,764,625
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
EXP |
Chlorpromazine results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:17512020 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of ALDH1A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Chlorpromazine results in increased expression of ALDOA mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Chlorpromazine inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AP1S1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Apoc4 |
apolipoprotein C4 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOC4 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:79,335,745...79,339,942
Ensembl chr 1:79,335,745...79,339,981
|
|
G |
Apof |
apolipoprotein F |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of APOF mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Areg |
amphiregulin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of AREG mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arfgef2 |
ARF guanine nucleotide exchange factor 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ARFGEF2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:155,547,504...155,633,652
Ensembl chr 3:155,547,538...155,630,856
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ARHGEF10 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173
|
|
G |
Asah1 |
N-acylsphingosine amidohydrolase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of ASAH1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Chlorpromazine results in increased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf4 |
activating transcription factor 4 |
affects activity multiple interactions |
EXP ISO |
Chlorpromazine affects the activity of ATF4 protein [Chlorpromazine co-treated with Cholic Acids] affects the expression of ATF4 mRNA |
CTD |
PMID:25596134 PMID:27344345 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:19441803 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Avp |
arginine vasopressin |
increases expression multiple interactions |
ISO EXP |
Chlorpromazine results in increased expression of AVP protein Chlorpromazine inhibits the reaction [Lithium results in increased expression of AVP protein] |
CTD |
PMID:3567260 PMID:3976404 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bag4 |
BAG cochaperone 4 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of BAG4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:66,288,678...66,305,893
Ensembl chr16:66,288,678...66,308,663
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of BCL2L1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
affects response to substance affects expression |
ISO EXP |
BDNF affects the susceptibility to Chlorpromazine Chlorpromazine affects the expression of BDNF mRNA |
CTD |
PMID:18408624 PMID:31324950 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BHLHE40 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of BIRC2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of BIRC5 mRNA; Chlorpromazine results in decreased expression of BIRC5 mRNA |
CTD |
PMID:15924885 PMID:30703373 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
EXP |
Chlorpromazine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BTG2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Btg3 |
BTG anti-proliferation factor 3 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of BTG3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr11:17,030,156...17,046,069
Ensembl chr11:17,030,160...17,046,170
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C3 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C6 |
complement C6 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of C6 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:53,846,028...53,921,279
Ensembl chr 2:53,851,985...53,921,275
|
|
G |
Calcr |
calcitonin receptor |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 4:32,615,955...32,691,075
Ensembl chr 4:31,661,273...31,736,392
|
|
G |
Calr |
calreticulin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CALR mRNA |
CTD |
PMID:18246545 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Cat |
catalase |
multiple interactions decreases expression decreases activity |
EXP ISO |
carvedilol inhibits the reaction [Chlorpromazine results in decreased expression of CAT protein]; zolpidem inhibits the reaction [Chlorpromazine results in decreased activity of CAT] |
CTD |
PMID:12010767 PMID:17513028 PMID:25449126 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CCN2 mRNA; Chlorpromazine results in decreased expression of CCN2 protein |
CTD |
PMID:30703373 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccn3 |
cellular communication network factor 3 |
affects expression |
EXP |
Chlorpromazine affects the expression of CCN3 mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:86,094,000...86,101,019
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCNB2 mRNA; Chlorpromazine results in decreased expression of CCNB2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CCND1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCND3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CCNF mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [platycodin D results in decreased expression of and results in increased secretion of CD274 protein] |
CTD |
PMID:31150782 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions decreases expression |
ISO |
Chlorpromazine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD44 protein] Chlorpromazine results in decreased expression of CD44 protein |
CTD |
PMID:9929743 PMID:30703373 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Chlorpromazine results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CDK5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of CDK7 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:31,840,558...31,865,422
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP |
[EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA] |
CTD |
PMID:20368687 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CDKN2C mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CES2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cfh |
complement factor H |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CFH mRNA |
CTD |
PMID:27344345 |
|
NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CGREF1 mRNA |
CTD |
PMID:17202759 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CHTF18 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:14,743,006...14,751,044
Ensembl chr10:14,742,621...14,751,050
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CITED2 mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of CKS2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of CLCF1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 1:201,507,763...201,517,607
Ensembl chr 1:201,507,859...201,517,605
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of COL18A1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Chlorpromazine results in increased expression of COL1A1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of COL4A1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Cort |
cortistatin |
affects expression |
EXP |
Chlorpromazine affects the expression of CORT mRNA |
CTD |
PMID:31324950 |
|
NCBI chr 5:159,560,591...159,562,032
|
|
G |
Cox8a |
cytochrome c oxidase subunit 8A |
affects expression increases expression |
EXP |
Chlorpromazine affects the expression of COX8A mRNA Chlorpromazine results in increased expression of COX8A mRNA |
CTD |
PMID:18246545 |
|
NCBI chr 1:204,402,118...204,404,439
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cth |
cystathionine gamma-lyase |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of CTH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity decreases response to substance increases expression |
ISO EXP |
[Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1A1 mRNA]; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Chlorpromazine results in decreased activity of CYP1A1 protein CYP1A1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:17202759 PMID:18246545 PMID:18493746 PMID:25596134 PMID:26477383 PMID:29724254 PMID:33814510 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases response to substance increases expression increases oxidation affects expression decreases methylation |
ISO EXP |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP1A2 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; Chlorpromazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]; CYP1A2 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP1A2 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in increased expression of CYP1A2 mRNA CYP1A2 protein results in increased oxidation of Chlorpromazine Chlorpromazine affects the expression of CYP1A2 mRNA CYP1A2 protein results in decreased methylation of Chlorpromazine |
CTD |
PMID:18246545 PMID:18493746 PMID:19482014 PMID:20615392 PMID:23397584 PMID:25596134 PMID:26477383 PMID:27344345 More...
|
|
NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases response to substance decreases activity multiple interactions |
ISO |
CYP1B1 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP1B1 protein [Filipin co-treated with Chlorpromazine co-treated with Wortmannin] inhibits the reaction [Particulate Matter results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:26477383 PMID:29724254 PMID:33814510 |
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions decreases response to substance |
ISO |
[Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA] CYP2B6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:10037683 PMID:12049174 PMID:17041008 PMID:26477383 |
|
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases expression decreases response to substance |
EXP ISO |
Chlorpromazine results in decreased expression of CYP2C mRNA; Chlorpromazine results in decreased expression of CYP2C11 mRNA CYP2C18 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:18246545 PMID:26477383 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions decreases response to substance decreases activity affects methylation |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP2C19 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP2C19 protein CYP2C19 protein affects the methylation of Chlorpromazine |
CTD |
PMID:15135088 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases response to substance |
ISO |
CYP2C8 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases response to substance |
ISO |
[CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine; CYP2D6 protein results in increased metabolism of and results in increased activity of Chlorpromazine CYP2D6 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:19482014 PMID:23397584 PMID:26477383 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity decreases response to substance |
ISO |
Chlorpromazine results in decreased activity of CYP2E1 protein CYP2E1 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:15135088 PMID:26477383 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects methylation affects oxidation multiple interactions decreases response to substance decreases activity |
ISO |
CYP3A4 protein affects the methylation of Chlorpromazine CYP3A4 protein affects the oxidation of Chlorpromazine [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [CYP1A2 protein co-treated with CYP2C9 protein co-treated with CYP3A4 protein co-treated with CYP2D6 protein co-treated with CYP2C19 protein] affects the susceptibility to Chlorpromazine CYP3A4 protein results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of CYP3A4 protein |
CTD |
PMID:15135088 PMID:17041008 PMID:20615392 PMID:23397584 PMID:26477383 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
decreases response to substance |
ISO |
CYP3A5 protein results in decreased susceptibility to Chlorpromazine |
CTD |
PMID:26477383 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of CYP8B1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dao |
D-amino-acid oxidase |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of DAO protein |
CTD |
PMID:18615285 |
|
NCBI chr12:42,592,342...42,613,046
Ensembl chr12:42,592,343...42,612,741
|
|
G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr 7:70,807,455...70,822,067
Ensembl chr 7:70,807,581...70,822,078
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP |
Chlorpromazine results in increased expression of DDIT3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of DEPP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Drd1 |
dopamine receptor D1 |
decreases activity |
ISO |
Chlorpromazine results in decreased activity of DRD1 protein |
CTD |
PMID:23611293 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases response to substance decreases activity |
ISO |
DRD2 polymorphism results in decreased susceptibility to Chlorpromazine Chlorpromazine results in decreased activity of DRD2 protein |
CTD |
PMID:15694263 PMID:23611293 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression affects expression |
ISO |
Chlorpromazine analog results in increased expression of DUSP1 mRNA Chlorpromazine affects the expression of DUSP1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp9 |
dual specificity phosphatase 9 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of DUSP9 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:151,351,897...151,355,822
Ensembl chr X:151,351,897...151,355,821
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of E2F1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Egr1 |
early growth response 1 |
increases expression multiple interactions |
EXP |
Chlorpromazine results in increased expression of EGR1 [EGR1 binds to CDKN1A promoter] promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; EGR1 promotes the reaction [Chlorpromazine results in increased expression of CDKN1A mRNA]; MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1]; MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:20368687 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of EIF1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327 Ensembl chr 5:85,246,764...85,427,327
|
|
G |
Eno2 |
enolase 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of ENO2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
EXP |
Chlorpromazine results in increased expression of ERO1A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of F2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of FABP1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of FAS mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FBP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fbxo22 |
F-box protein 22 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of FBXO22 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:55,579,906...55,595,981
Ensembl chr 8:55,579,891...55,596,148
|
|
G |
Fech |
ferrochelatase |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of FECH mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
G |
Fetub |
fetuin B |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FETUB mRNA |
CTD |
PMID:27344345 |
|
NCBI chr11:78,082,158...78,093,022
Ensembl chr11:78,082,156...78,095,135
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGA mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FGF2 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of FGFR1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:73,194,631...73,249,855
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of FGR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Lipopolysaccharides results in decreased expression of FKBP5 protein] |
CTD |
PMID:21034739 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Chlorpromazine results in increased expression of FNDC4 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOS mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOSB mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression affects expression |
ISO |
Chlorpromazine analog results in increased expression of FOSL1 mRNA Chlorpromazine affects the expression of FOSL1 mRNA |
CTD |
PMID:15924885 PMID:20843724 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
affects expression |
ISO |
Chlorpromazine affects the expression of FOSL2 mRNA |
CTD |
PMID:20843724 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of FTH1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression decreases activity multiple interactions |
ISO EXP |
Chlorpromazine analog results in decreased expression of G6PD mRNA Chlorpromazine results in decreased activity of G6PD protein [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of G6PD protein] |
CTD |
PMID:15924885 PMID:33548410 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
decreases methylation multiple interactions |
ISO |
Chlorpromazine results in decreased methylation of GAD1 promoter Valproic Acid promotes the reaction [Chlorpromazine results in decreased methylation of GAD1 promoter] |
CTD |
PMID:19110320 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gcgr |
glucagon receptor |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GCGR mRNA |
CTD |
PMID:27344345 |
|
NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of GCLC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
EXP |
Chlorpromazine results in increased expression of GDF15 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Chlorpromazine results in increased expression of GDPD3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
|
|
G |
Gfap |
glial fibrillary acidic protein |
affects expression |
EXP |
Chlorpromazine affects the expression of GFAP mRNA |
CTD |
PMID:31324950 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
Chlorpromazine results in increased expression of GPNMB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases expression |
EXP |
Chlorpromazine results in increased expression of GPT protein |
CTD |
PMID:35722787 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of GSR protein |
CTD |
PMID:6693892 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of GSTA1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects activity |
EXP |
Chlorpromazine affects the activity of HIF1A protein |
CTD |
PMID:25596134 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Chlorpromazine results in increased expression of HMGCR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of HMGCS1 mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression affects expression |
ISO EXP |
Chlorpromazine results in increased expression of HMOX1 mRNA Chlorpromazine affects the expression of HMOX1 mRNA |
CTD |
PMID:15924885 PMID:25596134 PMID:31324950 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpn |
hepsin |
increases expression |
ISO |
Chlorpromazine results in increased expression of HPN mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
increases expression decreases expression |
EXP |
Chlorpromazine results in increased expression of HSPA2 mRNA Chlorpromazine results in decreased expression of HSPA2 mRNA; Chlorpromazine results in decreased expression of HSPA2 protein |
CTD |
PMID:36751017 |
|
NCBI chr 6:100,864,172...100,866,946
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
increases expression decreases expression |
EXP |
Chlorpromazine results in increased expression of HSPB1 mRNA Chlorpromazine results in decreased expression of HSPB1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of HSPD1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 9:64,073,610...64,084,332
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of HSPE1 mRNA |
CTD |
PMID:36751017 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Ibsp |
integrin-binding sialoprotein |
decreases expression multiple interactions |
EXP |
Chlorpromazine results in decreased expression of IBSP mRNA herbimycin inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA]; U 0126 inhibits the reaction [Chlorpromazine results in decreased expression of IBSP mRNA] |
CTD |
PMID:16294319 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Chlorpromazine promotes the reaction [PAM2-CSK4 results in increased expression of IFNB1 mRNA] |
CTD |
PMID:32796029 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifnlr1 |
interferon, lambda receptor 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of IFNLR1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 5:147,919,547...147,942,328
Ensembl chr 5:147,919,908...147,942,332
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of IKBKG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein]; Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:29594315 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine |
CTD |
PMID:19362101 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Chlorpromazine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Ins1 |
insulin 1 |
decreases secretion |
EXP |
Chlorpromazine results in decreased secretion of INS1 protein |
CTD |
PMID:18308779 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr13:35,025,160...35,052,937
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
EXP |
Chlorpromazine results in decreased expression of and results in decreased phosphorylation of IRS2 protein; Chlorpromazine results in decreased expression of and results in increased degradation of IRS2 protein |
CTD |
PMID:17512020 PMID:18308779 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Chlorpromazine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Chlorpromazine results in decreased activity of KCNH2 protein |
CTD |
PMID:15071359 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
decreases activity |
EXP |
Chlorpromazine results in decreased activity of KCNN2 protein |
CTD |
PMID:10915830 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions decreases expression |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLF4 mRNA Chlorpromazine results in decreased expression of KLF4 mRNA |
CTD |
PMID:27344345 PMID:30703373 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klkb1 |
kallikrein B1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KLKB1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of KNG1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lats1 |
large tumor suppressor kinase 1 |
increases phosphorylation |
ISO |
Chlorpromazine results in increased phosphorylation of LATS1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 1:3,980,801...4,014,029
Ensembl chr 1:2,160,411...2,193,640
|
|
G |
Ldhc |
lactate dehydrogenase C |
decreases activity multiple interactions |
EXP |
Chlorpromazine results in decreased activity of LDHC protein [Taurine co-treated with coenzyme Q10] inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; coenzyme Q10 inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein]; Taurine inhibits the reaction [Chlorpromazine results in decreased activity of LDHC protein] |
CTD |
PMID:33548410 |
|
NCBI chr 1:106,522,140...106,539,649
Ensembl chr 1:97,382,379...97,403,378
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Chlorpromazine results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
increases expression |
EXP |
Chlorpromazine results in increased expression of LEP protein |
CTD |
PMID:17512020 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lss |
lanosterol synthase |
increases expression |
ISO |
Chlorpromazine results in increased expression of LSS mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK1 protein] MAPK1 affects the reaction [Chlorpromazine results in increased expression of EGR1] |
CTD |
PMID:11014349 PMID:20368687 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MAPK14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases expression multiple interactions |
ISO EXP |
Chlorpromazine analog results in decreased expression of MAPK3 mRNA MAPK3 affects the reaction [Chlorpromazine results in increased expression of EGR1] Chlorpromazine inhibits the reaction [IL2 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11014349 PMID:15924885 PMID:20368687 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein; Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:23238562 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of MAPKAPK2 mRNA |
CTD |
PMID:19441803 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MCM3 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MCM5 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
EXP |
Chlorpromazine results in increased expression of MDM2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression |
ISO |
Chlorpromazine results in increased expression of MITF protein |
CTD |
PMID:25449126 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MKI67 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; Chlorpromazine inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein] |
CTD |
PMID:25200491 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msc |
musculin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of MSC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:4,547,335...4,553,206
Ensembl chr 5:4,547,405...4,553,203
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MSH2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 6:12,567,368...12,626,534
Ensembl chr 6:6,813,795...6,872,938
|
|
G |
Mst1 |
macrophage stimulating 1 |
increases phosphorylation |
ISO |
Chlorpromazine results in increased phosphorylation of MST1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 8:117,646,485...117,652,016
Ensembl chr 8:108,768,839...108,773,416
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of MT1A mRNA |
CTD |
PMID:8128501 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mybl2 |
MYB proto-oncogene like 2 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of MYBL2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of MYC mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
increases expression |
EXP |
Chlorpromazine results in increased expression of NAMPT mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nanog |
Nanog homeobox |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of NANOG mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Ndufs3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NDUFS3 protein |
CTD |
PMID:19441803 |
|
NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Cadmium Chloride results in decreased expression of and affects the localization of NECTIN2 protein] |
CTD |
PMID:25046863 |
|
NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360
|
|
G |
Nedd9 |
neural precursor cell expressed, developmentally down-regulated 9 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NEDD9 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019
|
|
G |
Nefh |
neurofilament heavy chain |
affects expression |
EXP |
Chlorpromazine affects the expression of NEFH mRNA |
CTD |
PMID:31324950 |
|
NCBI chr14:84,044,428...84,054,413
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression affects activity |
EXP |
Chlorpromazine results in decreased expression of NFE2L2 mRNA Chlorpromazine affects the activity of NFE2L2 protein |
CTD |
PMID:25596134 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ninj1 |
ninjurin 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of NINJ1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr17:15,452,804...15,461,684
Ensembl chr17:15,452,813...15,461,704
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
EXP |
Chlorpromazine results in increased expression of NPPB protein |
CTD |
PMID:36751017 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Chlorpromazine results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of NR1H4 mRNA |
CTD |
PMID:27765674 PMID:28391356 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression multiple interactions |
ISO |
Chlorpromazine analog results in increased expression of NR1I2 mRNA [Chlorpromazine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:15924885 PMID:17041008 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity increases expression multiple interactions |
ISO |
Chlorpromazine results in increased activity of NR1I3 protein Chlorpromazine results in increased expression of NR1I3 mRNA [Chlorpromazine co-treated with Cholic Acids] affects the expression of NR1I3 mRNA; [Chlorpromazine results in increased activity of NR1I3 protein alternative form] which results in increased expression of CYP2B6 mRNA; Chlorpromazine inhibits the reaction [Androstenols inhibits the reaction [NR1I3 protein results in increased expression of CYP2B6 mRNA]] NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP2B10 mRNA]; NR1I3 protein affects the reaction [Chlorpromazine results in increased expression of CYP3A11 mRNA] |
CTD |
PMID:10037683 PMID:12049174 PMID:12948398 PMID:17041008 PMID:22310298 PMID:27344345 More...
|
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein] |
CTD |
PMID:16581232 |
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Chlorpromazine results in increased expression of NUPR1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of ORC1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375
|
|
G |
Orm1 |
orosomucoid 1 |
affects binding multiple interactions |
ISO |
Chlorpromazine binds to ORM1 protein alternative form Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form] |
CTD |
PMID:8946472 |
|
NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of PDIA2 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931
|
|
G |
Pdia5 |
protein disulfide isomerase family A, member 5 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of PDIA5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:65,272,152...65,359,087
Ensembl chr11:65,272,155...65,359,084
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PDK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PDK4 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
increases expression |
ISO |
Chlorpromazine results in increased expression of PHYH mRNA |
CTD |
PMID:15342952 |
|
NCBI chr17:73,329,461...73,346,359
Ensembl chr17:73,329,082...73,346,409
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of PIAS1 mRNA |
CTD |
PMID:21683644 |
|
NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of PIM1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,554,921...7,559,174
|
|
G |
Pir |
pirin |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of PIR mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:30,108,536...30,219,269
Ensembl chr X:30,108,538...30,219,218
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of PLIN2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pmepa1 |
prostate transmembrane protein, androgen induced 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of PMEPA1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:162,011,884...162,060,343
Ensembl chr 3:162,012,751...162,060,454
|
|
G |
Pola1 |
DNA polymerase alpha 1, catalytic subunit |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of POLA1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536
|
|
G |
Pold4 |
DNA polymerase delta 4, accessory subunit |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of POLD4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 1:201,526,591...201,528,406
Ensembl chr 1:201,526,665...201,528,401
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of POU5F1 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects activity |
EXP |
Chlorpromazine affects the activity of PPARG protein |
CTD |
PMID:25596134 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
EXP |
Chlorpromazine results in increased expression of PPP1R15A mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
decreases phosphorylation |
EXP |
Chlorpromazine results in decreased phosphorylation of PRKAA1 protein |
CTD |
PMID:17512020 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Chlorpromazine results in increased expression of PRL protein |
CTD |
PMID:718334 PMID:996201 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Rara |
retinoic acid receptor, alpha |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RARA mRNA |
CTD |
PMID:18246545 |
|
NCBI chr10:84,379,780...84,424,371
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rnd1 |
Rho family GTPase 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RND1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 7:131,700,321...131,707,392
Ensembl chr 7:129,821,311...129,828,399
|
|
G |
Rnd3 |
Rho family GTPase 3 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RND3 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327
|
|
G |
Rnf121 |
ring finger protein 121 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of RNF121 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:156,377,368...156,439,936
Ensembl chr 1:156,377,364...156,446,826
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of RUNX1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects response to substance |
ISO |
RXRG protein affects the susceptibility to Chlorpromazine |
CTD |
PMID:10336693 |
|
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SAT1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813
|
|
G |
Sc5d |
sterol-C5-desaturase |
increases expression |
ISO |
Chlorpromazine results in increased expression of SC5D mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273
|
|
G |
Serpina3n |
serpin family A member 3N |
increases expression |
ISO |
Chlorpromazine results in increased expression of SERPINA3 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of SERPINH1 mRNA |
CTD |
PMID:35708773 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SESN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:46,876,918...46,970,010
Ensembl chr20:45,294,871...45,387,697
|
|
G |
Sik1 |
salt-inducible kinase 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SIK1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr20:9,949,407...9,959,036
Ensembl chr20:9,947,396...9,958,991
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression increases expression |
EXP ISO |
Chlorpromazine results in decreased expression of SLC10A1 mRNA Chlorpromazine results in increased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28391356 PMID:35708773 |
|
NCBI chr 6:106,344,319...106,357,944
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc12a8 |
solute carrier family 12, member 8 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC12A8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr11:67,116,876...67,266,548
Ensembl chr11:67,116,877...67,266,834
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
multiple interactions decreases activity |
EXP |
Chlorpromazine inhibits the reaction [SLC19A1 protein results in increased uptake of Methotrexate] Chlorpromazine results in decreased activity of SLC19A1 protein |
CTD |
PMID:17482559 |
|
NCBI chr20:11,583,928...11,601,959
Ensembl chr20:11,584,411...11,601,972
|
|
G |
Slc1a5 |
solute carrier family 1 member 5 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC1A5 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:77,456,849...77,470,952
Ensembl chr 1:77,456,694...77,470,952
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC22A7 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Copper affects the localization of SLC31A1 protein] |
CTD |
PMID:12501239 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC3A2 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SLC51B mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc6a6 |
solute carrier family 6 member 6 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SLC6A6 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:124,195,186...124,268,880
Ensembl chr 4:124,195,218...124,268,875
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of SLCO2B1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [Copper inhibits the reaction [Trientine results in decreased activity of SOD1 protein]] |
CTD |
PMID:22362149 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of SOX2 mRNA |
CTD |
PMID:30703373 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of SPP1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Spsb1 |
splA/ryanodine receptor domain and SOCS box containing 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of SPSB1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:160,358,292...160,418,541
Ensembl chr 5:160,358,308...160,418,468
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
EXP |
Chlorpromazine inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased phosphorylation of SRC protein] |
CTD |
PMID:29702141 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Chlorpromazine results in increased cleavage of and results in increased activity of SREBF2 protein |
CTD |
PMID:17052361 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
increases expression |
EXP |
Chlorpromazine results in increased expression of STRBP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 3:21,328,310...21,467,753
Ensembl chr 3:21,337,855...21,414,949
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
Chlorpromazine inhibits the reaction [Tretinoin results in increased activity of STS protein] |
CTD |
PMID:16178010 |
|
NCBI chr X:46,102,524...46,110,868
Ensembl chr X:42,225,372...42,233,402
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tf |
transferrin |
affects localization |
ISO |
Chlorpromazine affects the localization of TF protein |
CTD |
PMID:12501239 |
|
NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of TFDP1 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817
|
|
G |
Tiparp |
TCDD-inducible poly(ADP-ribose) polymerase |
increases expression |
EXP |
Chlorpromazine results in increased expression of TIPARP mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 2:149,753,682...149,780,327
Ensembl chr 2:149,753,682...149,780,327
|
|
G |
Tirap |
TIR domain containing adaptor protein |
multiple interactions |
ISO |
TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased phosphorylation of MAPK8 protein]; TIRAP gene mutant form inhibits the reaction [Chlorpromazine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4]; TIRAP protein results in increased susceptibility to [Chlorpromazine co-treated with lipoteichoic acid] |
CTD |
PMID:23238562 |
|
NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression increases response to substance multiple interactions |
ISO |
Chlorpromazine analog results in decreased expression of TNF protein; Chlorpromazine results in decreased expression of TNF mRNA TNF protein results in increased susceptibility to Chlorpromazine [Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein; [Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein; Chlorpromazine inhibits the reaction [[hydroquinone results in increased expression of TNF protein] which results in increased susceptibility to Methacholine Chloride]; Chlorpromazine inhibits the reaction [hydroquinone results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Chlorpromazine]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of TNF protein]; TIRAP gene mutant form inhibits the reaction [[Chlorpromazine co-treated with lipoteichoic acid] results in increased expression of TNF protein] [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Chlorpromazine; Chlorpromazine results in decreased expression of and results in decreased activity of TNF protein |
CTD |
PMID:8550079 PMID:15052360 PMID:19362101 PMID:20371967 PMID:22414385 PMID:23238562 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip8 |
TNF alpha induced protein 8 |
increases expression |
EXP |
Chlorpromazine results in increased expression of TNFAIP8 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr18:43,183,854...43,299,512
Ensembl chr18:43,183,916...43,299,517
|
|
G |
Tnfrsf14 |
TNF receptor superfamily member 14 |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of TNFRSF14 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 5:165,486,069...165,494,421
Ensembl chr 5:165,484,262...165,493,703
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases activity multiple interactions |
ISO |
Chlorpromazine results in decreased activity of TNFSF11; Chlorpromazine results in decreased activity of TNFSF11 protein Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CALCR mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CAR2 mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of DCSTAMP mRNA]; Chlorpromazine inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA] |
CTD |
PMID:21869564 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
EXP |
Chlorpromazine affects the activity of TP53 protein |
CTD |
PMID:25596134 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trafd1 |
TRAF type zinc finger domain containing 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of TRAFD1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr12:35,165,606...35,179,525
Ensembl chr12:35,165,606...35,179,525
|
|
G |
Tuba1a |
tubulin, alpha 1A |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of TUBA1A mRNA |
CTD |
PMID:27015953 |
|
NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of TXN1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
[Chlorpromazine co-treated with Cholic Acids] affects the expression of TXNRD1 mRNA |
CTD |
PMID:27344345 |
|
NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
Chlorpromazine results in increased expression of TYR protein |
CTD |
PMID:25449126 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Ung |
uracil-DNA glycosylase |
decreases expression |
ISO |
Chlorpromazine analog results in decreased expression of UNG mRNA |
CTD |
PMID:15924885 |
|
NCBI chr12:48,145,838...48,154,789
Ensembl chr12:42,485,276...42,494,206
|
|
G |
Unkl |
unk like zinc finger |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of UNKL mRNA |
CTD |
PMID:25596134 |
|
NCBI chr10:14,206,125...14,252,226
Ensembl chr10:14,206,189...14,252,225
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Chlorpromazine analog results in increased expression of VEGFA mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfb |
vascular endothelial growth factor B |
increases expression |
EXP |
Chlorpromazine results in increased expression of VEGFB mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 1:204,172,297...204,178,046
Ensembl chr 1:204,172,225...204,177,944
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
EXP |
Chlorpromazine results in increased expression of WARS1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
increases expression |
ISO |
Chlorpromazine results in increased expression of WIPI1 mRNA |
CTD |
PMID:15342952 PMID:17175557 |
|
NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846
|
|
G |
Xbp1 |
X-box binding protein 1 |
affects activity decreases expression |
EXP |
Chlorpromazine affects the activity of XBP1 protein Chlorpromazine results in decreased expression of XBP1 mRNA |
CTD |
PMID:25596134 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xpc |
XPC complex subunit, DNA damage recognition and repair factor |
decreases expression |
EXP |
Chlorpromazine results in decreased expression of XPC mRNA |
CTD |
PMID:25596134 |
|
NCBI chr 4:123,993,670...124,020,922
Ensembl chr 4:123,993,666...124,021,010
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
decreases expression |
ISO |
Chlorpromazine results in decreased expression of XRCC4 mRNA |
CTD |
PMID:15924885 |
|
NCBI chr 2:20,948,464...21,197,705
Ensembl chr 2:20,951,200...21,197,808
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
multiple interactions |
ISO |
Chlorpromazine results in decreased expression of and results in increased phosphorylation of and affects the localization of YAP1 protein |
CTD |
PMID:30703373 |
|
NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Clopenthixol results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
ISO |
Droperidol results in decreased activity of KCNH2 protein Droperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium] |
CTD |
PMID:16757186 PMID:21158687 PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Droperidol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity |
ISO |
Flupenthixol analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; Flupenthixol analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine] Flupenthixol analog results in decreased activity of ABCB1 protein; Flupenthixol analog results in decreased activity of ABCB1 protein mutant form |
CTD |
PMID:7905786 PMID:12711602 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding |
ISO |
Flupenthixol binds to DRD1 protein |
CTD |
PMID:1352677 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Flupenthixol results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
ISO |
Flupenthixol results in decreased expression of PTGS1 protein |
CTD |
PMID:8897462 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Flupenthixol results in decreased expression of PTGS2 protein |
CTD |
PMID:8897462 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions decreases activity |
EXP |
[Fluphenazine co-treated with diphenyldiselenide] results in decreased activity of ALAD protein Fluphenazine results in decreased activity of ALAD protein |
CTD |
PMID:19486337 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Ankrd40 |
ankyrin repeat domain 40 |
increases expression |
EXP |
Fluphenazine results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320 Ensembl chr10:79,282,075...79,295,320
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Fluphenazine binds to and results in decreased activity of AR protein |
CTD |
PMID:17606915 |
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP |
diphenyldiselenide inhibits the reaction [Fluphenazine results in increased activity of CAT protein] |
CTD |
PMID:19486337 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
Fluphenazine results in decreased activity of CYP2C19 protein |
CTD |
PMID:15135088 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Fluphenazine results in decreased activity of CYP2E1 protein |
CTD |
PMID:15135088 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
Fluphenazine results in decreased activity of CYP3A4 protein |
CTD |
PMID:15135088 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding |
ISO |
Fluphenazine binds to DRD2 protein |
CTD |
PMID:17606915 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects binding |
ISO |
Fluphenazine binds to HTR2A protein |
CTD |
PMID:17606915 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
affects binding |
ISO |
Fluphenazine binds to HTR2C protein |
CTD |
PMID:17606915 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
Fluphenazine inhibits the reaction [NGF protein results in increased uptake of Calcium] |
CTD |
PMID:1374475 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Prl |
prolactin |
increases secretion |
ISO |
Fluphenazine results in increased secretion of PRL protein |
CTD |
PMID:9989566 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Fluphenazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Tac1 |
tachykinin, precursor 1 |
decreases expression |
ISO |
Fluphenazine results in decreased expression of TAC1 mRNA |
CTD |
PMID:15845098 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tfeb |
transcription factor EB |
affects localization |
ISO |
Fluphenazine affects the localization of TFEB protein |
CTD |
PMID:28366621 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression decreases activity |
ISO |
Haloperidol inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCB1 mRNA Haloperidol results in decreased activity of ABCB1 protein |
CTD |
PMID:15946544 PMID:16810505 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCC1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Haloperidol inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
decreases expression |
ISO |
Haloperidol results in decreased expression of ACADVL protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ACAT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [potassium bromate results in increased activity of ACHE protein] |
CTD |
PMID:37865952 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ACSL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [potassium bromate results in increased activity of ADA protein] |
CTD |
PMID:37865952 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam1a |
ADAM metallopeptidase domain 1a |
decreases expression |
EXP |
Haloperidol results in decreased expression of ADAM1A mRNA |
CTD |
PMID:16715494 |
|
NCBI chr12:35,017,433...35,020,300
Ensembl chr12:35,017,315...35,020,311
|
|
G |
Adcy5 |
adenylate cyclase 5 |
affects response to substance multiple interactions |
ISO |
ADCY5 protein affects the susceptibility to Haloperidol SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Haloperidol] |
CTD |
PMID:12223546 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
ISO |
Haloperidol affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adora2a |
adenosine A2a receptor |
affects response to substance |
ISO |
ADORA2A protein affects the susceptibility to Haloperidol |
CTD |
PMID:11172060 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adsl |
adenylosuccinate lyase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ADSL protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of AGPAT1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:4,135,955...4,144,880
Ensembl chr20:4,135,957...4,145,278
|
|
G |
Agps |
alkylglycerone phosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of AGPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830
|
|
G |
Ak4 |
adenylate kinase 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of AK4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AKT1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases expression |
EXP |
Haloperidol results in increased expression of AKT2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ALDH18A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ANKHD1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Ankrd40 |
ankyrin repeat domain 40 |
increases expression |
EXP |
Haloperidol results in increased expression of TMPRSS2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320 Ensembl chr10:79,282,075...79,295,320
|
|
G |
Ap2a2 |
adaptor related protein complex 2 subunit alpha 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AP2A2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:196,652,315...196,725,609
Ensembl chr 1:196,652,337...196,725,603
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
affects expression |
EXP |
Haloperidol affects the expression of AP2B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:68,099,397...68,205,023
Ensembl chr10:68,099,547...68,205,013
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
increases expression |
ISO |
Haloperidol results in increased expression of AP2M1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
|
|
G |
Ap3b1 |
adaptor related protein complex 3 subunit beta 1 |
increases expression |
ISO |
Haloperidol results in increased expression of AP3B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:27,331,241...27,535,683
Ensembl chr 2:25,600,040...25,800,935
|
|
G |
Apod |
apolipoprotein D |
increases expression |
ISO |
Haloperidol results in increased expression of APOD mRNA |
CTD |
PMID:14647396 |
|
NCBI chr11:82,936,216...82,957,264
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of APPL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ARC mRNA 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of ARC mRNA] |
CTD |
PMID:18208916 PMID:19695244 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arf1 |
ARF GTPase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Arf3 |
ARF GTPase 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G |
Arl3 |
ARF like GTPase 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:255,342,078...255,388,087
Ensembl chr 1:245,400,550...245,446,820
|
|
G |
Arl5a |
ARF like GTPase 5A |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL5A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
increases expression |
ISO |
Haloperidol results in increased expression of ARPC4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Haloperidol results in decreased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Haloperidol results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1B2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598 Ensembl chr 8:96,910,309...96,941,598
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of ATP2A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp6v1b1 |
ATPase H+ transporting V1 subunit B1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:16465460 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AXIN2 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of BAX protein Haloperidol results in increased expression of BAX mRNA; Haloperidol results in increased expression of BAX protein |
CTD |
PMID:16462815 PMID:17069804 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat2 |
branched chain amino acid transaminase 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of BCAT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:96,040,407...96,060,008
Ensembl chr 1:96,042,625...96,060,007
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Haloperidol results in increased expression of BCL2 protein |
CTD |
PMID:17069804 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression decreases expression |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein] Haloperidol results in increased expression of BCL2L1 protein |
CTD |
PMID:16462815 PMID:17805306 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression decreases expression |
EXP ISO |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; Haloperidol inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] Haloperidol results in increased expression of BDNF mRNA Haloperidol results in increased expression of BDNF protein Haloperidol inhibits the reaction [Cocaine results in decreased expression of BDNF protein] Haloperidol results in decreased expression of BDNF mRNA; Haloperidol results in decreased expression of BDNF protein |
CTD |
PMID:11488957 PMID:12393228 PMID:12478621 PMID:15168214 PMID:17442543 PMID:17805306 PMID:18208916 PMID:20554863 PMID:29182611 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
affects expression |
EXP |
Haloperidol affects the expression of BET1L mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of BOP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:110,052,716...110,076,529
Ensembl chr 7:108,172,066...108,195,931
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
decreases expression |
ISO |
Haloperidol results in decreased expression of BPTF mRNA |
CTD |
PMID:14647396 |
|
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
decreases expression |
EXP ISO |
Haloperidol results in decreased expression of CACNA1A mRNA |
CTD |
PMID:14647396 PMID:16715494 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
affects activity |
EXP |
Haloperidol affects the activity of CALCA protein |
CTD |
PMID:10075105 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Haloperidol results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol results in decreased expression of and results in decreased phosphorylation of CAMK2A protein Haloperidol results in increased expression of CAMK2A mRNA Haloperidol results in decreased expression of CAMK2A protein |
CTD |
PMID:15860345 PMID:18061412 PMID:19289156 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2D mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of CAMK4 protein Haloperidol results in increased expression of CAMK4 mRNA |
CTD |
PMID:15860345 PMID:19289156 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:15168214 PMID:17805306 PMID:18590723 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity decreases expression |
EXP ISO |
Carvedilol inhibits the reaction [Haloperidol results in decreased expression of CAT protein]; Haloperidol results in decreased activity of and results in decreased expression of CAT protein; Zolpidem inhibits the reaction [Haloperidol results in decreased activity of CAT] Haloperidol results in decreased activity of CAT protein Cannabidiol inhibits the reaction [Haloperidol results in decreased activity of CAT protein] |
CTD |
PMID:12010767 PMID:12482469 PMID:16564057 PMID:17513028 PMID:30217539 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CBX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccdc121 |
coiled-coil domain containing 121 |
increases expression |
ISO |
Haloperidol results in increased expression of CCDC121 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:24,970,845...24,973,451
Ensembl chr 6:24,970,833...24,973,478
|
|
G |
Cck |
cholecystokinin |
increases expression |
EXP |
Haloperidol results in increased expression of CCK mRNA |
CTD |
PMID:10974607 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CCND1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Haloperidol results in increased expression of CCND3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
EXP |
Haloperidol results in increased expression of CCNL1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CCT8 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
EXP |
Haloperidol results in increased expression of CDC42 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:154,838,478...154,876,629
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cfap161 |
cilia and flagella associated protein 161 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CFAP161 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:147,152,923...147,177,821
Ensembl chr 1:137,743,784...137,768,730
|
|
G |
Cfdp1 |
craniofacial development protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CFDP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,718,313...39,823,824
Ensembl chr19:39,718,347...39,823,824
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
ISO |
Haloperidol results in increased expression of CFL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chl1 |
cell adhesion molecule L1-like |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHL1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:136,291,504...136,505,830
Ensembl chr 4:136,291,463...136,503,265
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
Haloperidol results in increased expression of CHORDC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
ISO |
CHRM4 affects the susceptibility to Haloperidol |
CTD |
PMID:21269601 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Cldn11 |
claudin 11 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CLDN11 mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Clta |
clathrin, light chain A |
affects expression |
EXP |
Haloperidol affects the expression of CLTA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Cltb |
clathrin, light chain B |
decreases expression |
EXP |
Haloperidol results in decreased expression of CLTB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:10,001,512...10,019,201
Ensembl chr17:10,001,513...10,019,169
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CMYA5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:24,279,520...24,378,253
Ensembl chr 2:24,279,528...24,378,364
|
|
G |
Cnot3 |
CCR4-NOT transcription complex, subunit 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNOT3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,555,924...65,572,167
Ensembl chr 1:65,555,924...65,572,167
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases methylation |
ISO EXP |
CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]] Haloperidol results in increased methylation of CNR1 promoter Haloperidol inhibits the reaction [Methylazoxymethanol Acetate results in decreased methylation of CNR1 promoter] |
CTD |
PMID:28017790 PMID:30496751 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Coil |
coilin |
increases expression |
EXP |
Haloperidol results in increased expression of COIL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:73,789,077...73,810,378
Ensembl chr10:73,789,488...73,810,393
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of COPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of COPS4 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
|
|
G |
Cpn1 |
carboxypeptidase N subunit 1 |
increases expression |
EXP |
Haloperidol results in increased expression of CPN1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:242,844,575...242,873,465
Ensembl chr 1:242,844,212...242,873,465
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CPNE3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases expression increases activity increases phosphorylation |
ISO EXP |
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of CREB1 protein] Haloperidol results in increased expression of CREB1 mRNA; Haloperidol results in increased expression of CREB1 protein Amphetamine affects the reaction [Haloperidol results in increased activity of CREB1 protein modified form] |
CTD |
PMID:12125044 PMID:12871586 PMID:26894264 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of CRHBP mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRY1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CSNK2A1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Haloperidol results in increased expression of CST3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CTNNA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Haloperidol results in decreased expression of CTNNB1 mRNA Haloperidol results in increased expression of CTNNB1 protein DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 PMID:18797397 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
EXP |
Haloperidol results in increased expression of CTRL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr19:33,827,279...33,829,129
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Ctsk |
cathepsin K |
increases expression |
EXP |
Haloperidol results in increased expression of CTSK mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CYB5R1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 protein polymorphism affects the susceptibility to Haloperidol |
CTD |
PMID:15538130 |
|
NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dcaf6 |
DDB1 and CUL4 associated factor 6 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DCAF6 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr13:77,626,257...77,727,645
Ensembl chr13:77,626,307...77,727,512
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of DCLK1 mRNA |
CTD |
PMID:15860345 PMID:18797397 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
increases expression |
ISO |
Haloperidol results in increased expression of DDX27 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:176,163,220...176,182,418
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of DDX46 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DDX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283
|
|
G |
Dennd10 |
DENN domain containing 10 |
increases expression |
EXP |
Haloperidol results in increased expression of DENND10 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:259,950,955...259,974,459
Ensembl chr 1:259,950,866...259,974,455
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of DEPP1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of DGKA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Dhx36 |
DEAH-box helicase 36 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DHX36 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:146,856,469...146,894,577
Ensembl chr 2:146,856,469...146,894,572
|
|
G |
Dhx38 |
DEAH-box helicase 38 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DHX38 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:37,512,893...37,530,135
Ensembl chr19:37,512,891...37,530,140
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
decreases expression |
EXP |
Haloperidol results in decreased expression of DLAT mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479 Ensembl chr 1:50,978,051...51,004,479
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Haloperidol results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:153,864,545...155,916,238
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dnah1 |
dynein, axonemal, heavy chain 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of DNAH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:6,462,419...6,523,545
Ensembl chr16:6,456,002...6,518,350
|
|
G |
Dnah3 |
dynein, axonemal, heavy chain 3 |
increases expression |
ISO |
Haloperidol results in increased expression of DNAH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:183,738,013...183,910,831
Ensembl chr 1:174,306,644...174,479,474
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of DNAJB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of DNAJB11 protein Haloperidol results in increased expression of DNAJB11 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpf1 |
double PHD fingers 1 |
increases expression |
ISO |
Haloperidol results in increased expression of DPF1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dr1 |
down-regulator of transcription 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:1,458,223...1,469,578
Ensembl chr14:1,458,223...1,469,638
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding increases expression decreases expression affects activity |
ISO EXP |
Haloperidol binds to DRD1 protein Haloperidol results in increased expression of DRD1 protein Haloperidol results in decreased expression of DRD1 mRNA Haloperidol affects the activity of DRD1 protein |
CTD |
PMID:8750706 PMID:8794996 PMID:12887421 PMID:16983399 PMID:23611293 |
|
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding affects activity multiple interactions increases expression affects response to substance |
ISO EXP |
DRD2 protein binds to Haloperidol; DRD2 protein binds to Haloperidol analog; Haloperidol binds to DRD2 protein Haloperidol affects the activity of DRD2 protein [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; cyclo(leucylglycine) inhibits the reaction [Haloperidol results in increased expression of DRD2 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein]; felbamate inhibits the reaction [Haloperidol affects the activity of DRD2 protein]; Haloperidol binds to and results in decreased activity of DRD2 protein; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol inhibits the reaction [iodosulpride binds to DRD2 protein]; Haloperidol inhibits the reaction [Spiperone binds to DRD2 protein]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; zinc chloride inhibits the reaction [Haloperidol binds to DRD2 protein] Haloperidol results in increased expression of DRD2; Haloperidol results in increased expression of DRD2 mRNA; Haloperidol results in increased expression of DRD2 protein Haloperidol binds to DRD2; Haloperidol binds to DRD2 protein; Haloperidol binds to DRD2 protein alternative form [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Ethanol; [Haloperidol results in increased expression of DRD2 protein] which results in decreased susceptibility to Pentobarbital; Haloperidol binds to and results in decreased activity of DRD2 protein DRD2 affects the susceptibility to Haloperidol; DRD2 protein affects the susceptibility to Haloperidol Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 mRNA]; Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 protein] |
CTD |
PMID:1351265 PMID:1361536 PMID:1380082 PMID:2945998 PMID:7845605 PMID:7878047 PMID:8115415 PMID:8200438 PMID:8794996 PMID:9109525 PMID:9808703 PMID:10720636 PMID:10936494 PMID:11172060 PMID:11927170 PMID:11997696 PMID:12191584 PMID:12476322 PMID:14552778 PMID:15716360 PMID:16033416 PMID:16144542 PMID:18295747 PMID:19120057 PMID:20361897 PMID:20730801 PMID:23611293 More...
|
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
affects binding multiple interactions |
ISO EXP |
DRD3 protein binds to Haloperidol analog Haloperidol affects the reaction [Methylazoxymethanol Acetate results in increased expression of DRD3 mRNA] |
CTD |
PMID:14552778 PMID:32360362 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Drd4 |
dopamine receptor D4 |
affects activity affects binding |
ISO EXP |
Haloperidol affects the activity of DRD4 protein Haloperidol binds to Drd4 protein |
CTD RGD |
PMID:23611293 PMID:8078498 |
RGD:7248459 |
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Drp2 |
dystrophin related protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of DRP2 mRNA alternative form |
CTD |
PMID:16715494 |
|
NCBI chr X:97,607,577...97,658,117
Ensembl chr X:97,607,719...97,655,684
|
|
G |
Dtnbp1 |
dystrobrevin binding protein 1 |
increases response to substance affects response to substance |
ISO |
DTNBP1 gene polymorphism results in increased susceptibility to Haloperidol DTNBP1 protein affects the susceptibility to Haloperidol |
CTD |
PMID:19369910 |
|
NCBI chr17:19,891,313...19,982,770
Ensembl chr17:19,685,215...19,776,661
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:17,184,853...17,187,646
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of EEF1G protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Egr1 |
early growth response 1 |
affects expression multiple interactions increases expression |
EXP ISO |
Haloperidol affects the expression of EGR1 protein Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]; OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] Haloperidol results in increased expression of EGR1 mRNA; Haloperidol results in increased expression of EGR1 protein |
CTD |
PMID:12243769 PMID:16452686 PMID:17028028 PMID:17913375 PMID:18208916 PMID:19695244 PMID:20184921 More...
|
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
affects expression increases expression decreases expression |
ISO EXP |
Haloperidol affects the expression of EGR2 mRNA Haloperidol results in increased expression of EGR2 mRNA Haloperidol results in decreased expression of EGR2 protein |
CTD |
PMID:17028028 PMID:18208916 PMID:19401217 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eif2b5 |
eukaryotic translation initiation factor 2B subunit epsilon |
increases expression |
ISO |
Haloperidol results in increased expression of EIF2B5 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:80,394,433...80,404,468
Ensembl chr11:80,394,433...80,404,419
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of EIF5A protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases phosphorylation multiple interactions |
ISO EXP |
Haloperidol results in increased phosphorylation of ELK1 protein Nifedipine affects the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:12871586 PMID:17913375 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Eno1 |
enolase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ENO1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:166,002,867...166,014,252
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:17805306 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ERAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Haloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ERBB4 protein Haloperidol results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ergic1 |
endoplasmic reticulum-golgi intermediate compartment 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of ERGIC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:16,531,192...16,626,974
Ensembl chr10:16,531,194...16,626,957
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Haloperidol results in decreased expression of EZR protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
affects response to substance increases expression |
ISO |
FABP3 affects the susceptibility to Haloperidol Haloperidol results in increased expression of FABP3 protein |
CTD |
PMID:20181611 PMID:34122009 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Haloperidol results in increased expression of FASN mRNA |
CTD |
PMID:16027736 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
haloperidol inhibits the reaction [ethanol increases expression of FGF2 mRNA in dorsal striatum] |
RGD |
PMID:28821667 |
RGD:405855870 |
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of FLT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Haloperidol results in increased expression of FNDC4 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin affects the reaction [Haloperidol results in increased expression of FOS protein]; Dizocilpine Maleate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; ifenprodil inhibits the reaction [Haloperidol results in increased expression of FOS protein]; tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]; traxoprodil mesylate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; WAY 100135 inhibits the reaction [tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]] Haloperidol results in increased expression of FOS mRNA; Haloperidol results in increased expression of FOS protein Haloperidol results in decreased expression of FOS mRNA; Haloperidol results in decreased expression of FOS protein 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; Clozapine affects the reaction [Haloperidol results in increased expression of FOS protein]; Dronabinol promotes the reaction [Haloperidol results in increased expression of FOS protein]; Nifedipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Nimodipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Propranolol inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Theophylline inhibits the reaction [Haloperidol results in increased expression of FOS mRNA] |
CTD |
PMID:1393566 PMID:9571656 PMID:9748542 PMID:10199625 PMID:10435392 PMID:11166331 PMID:11409749 PMID:11440804 PMID:11516571 PMID:11602683 PMID:11997696 PMID:12093589 PMID:12125044 PMID:12243769 PMID:12464447 PMID:15120589 PMID:15140647 PMID:17028028 PMID:17913375 PMID:18208916 PMID:18295747 PMID:18521575 PMID:18585397 PMID:18789920 PMID:19352073 PMID:19695244 More...
|
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Haloperidol results in increased expression of FOSB protein alternative form Haloperidol results in increased expression of FOSB modified form; Haloperidol results in increased expression of FOSB mRNA; Haloperidol results in increased expression of FOSB protein 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOSB mRNA] |
CTD |
PMID:8714707 PMID:11180499 PMID:12243769 PMID:15579174 PMID:19695244 PMID:24067299 More...
|
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Amphetamine affects the reaction [Haloperidol results in increased expression of FOSL1 protein] Haloperidol results in increased expression of FOSL1 mRNA; Haloperidol results in increased expression of FOSL1 protein |
CTD |
PMID:12125044 PMID:18208916 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Haloperidol results in increased expression of FOSL2 mRNA |
CTD |
PMID:12243769 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions increases phosphorylation affects response to substance |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] Haloperidol results in increased phosphorylation of FYN protein FYN protein affects the susceptibility to Haloperidol |
CTD |
PMID:16407246 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of GABRA1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression |
EXP |
Haloperidol results in increased expression of GABRB1 mRNA; Haloperidol results in increased expression of GABRB1 protein |
CTD |
PMID:26894264 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of GABRB3 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions increases expression decreases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein Haloperidol results in increased expression of GAD1 mRNA Haloperidol results in decreased expression of GAD1 mRNA; Haloperidol results in decreased expression of GAD1 protein |
CTD |
PMID:12887421 PMID:14519413 PMID:15061247 PMID:15967061 PMID:18923069 PMID:19359144 More...
|
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GAD2 mRNA; Haloperidol results in decreased expression of GAD2 protein Haloperidol results in increased expression of GAD2 mRNA |
CTD |
PMID:18923069 PMID:19359144 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GALNT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
EXP |
Haloperidol results in increased expression of GAPDH mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gda |
guanine deaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of GDA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Haloperidol results in increased expression of GDPD3 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of GFAP protein |
CTD |
PMID:34122009 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gimap5 |
GTPase, IMAP family member 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GIMAP5 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 4:77,693,417...77,701,025
Ensembl chr 4:77,687,564...77,703,086
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GJA1 protein |
CTD |
PMID:18585900 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GLO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Haloperidol results in decreased expression of GLUL mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gna12 |
G protein subunit alpha 12 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNA12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GNAO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:11,034,874...11,192,531
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnas |
GNAS complex locus |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [manganese chloride results in increased secretion of GNRH1 protein] |
CTD |
PMID:18603625 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
affects expression multiple interactions |
EXP ISO |
Haloperidol affects the expression of GOT2 mRNA [Cuprizone co-treated with Haloperidol] results in increased expression of GOT2 protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of GPX1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIA1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
increases expression |
EXP |
Haloperidol results in increased expression of GRIK2 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375
|
|
G |
Grik4 |
glutamate ionotropic receptor kainate type subunit 4 |
increases expression |
EXP |
Haloperidol results in increased expression of GRIK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:42,905,056...43,193,751
|
|
G |
Grik5 |
glutamate ionotropic receptor kainate type subunit 5 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of GRIK5 mRNA |
CTD |
PMID:14647396 PMID:15860345 |
|
NCBI chr 1:80,605,878...80,667,896
Ensembl chr 1:80,605,892...80,667,125
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GRIN1 mRNA Haloperidol results in increased expression of GRIN1 mRNA |
CTD |
PMID:12020038 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIN2A mRNA; Haloperidol results in decreased expression of GRIN2A protein |
CTD |
PMID:12608697 PMID:15860345 PMID:18061412 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions increases phosphorylation |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] |
CTD |
PMID:16407246 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Grin2c |
glutamate ionotropic receptor NMDA type subunit 2C |
increases expression |
EXP |
Haloperidol results in increased expression of GRIN2C mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRIN2D mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Grin3b |
glutamate ionotropic receptor NMDA type subunit 3B |
increases expression |
EXP |
Haloperidol results in increased expression of GRIN3B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:9,730,861...9,737,183
Ensembl chr 7:9,730,862...9,737,183
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GRK6 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
increases expression |
EXP |
Haloperidol results in increased expression of GRM1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Grm2 |
glutamate metabotropic receptor 2 |
increases expression |
EXP |
Haloperidol results in increased expression of GRM2 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 8:107,280,099...107,293,159
Ensembl chr 8:107,280,099...107,293,146
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of GSK3A protein DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein] |
CTD |
PMID:16144542 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein] Haloperidol results in increased expression of GSK3B mRNA; Haloperidol results in increased expression of GSK3B protein |
CTD |
PMID:16144542 PMID:19359144 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
EXP |
Haloperidol results in increased expression of GSTM1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GSTM2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:198,312,179...198,316,962
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [GSTP1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of GSTP1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gtf2e1 |
general transcription factor IIE subunit 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of GTF2E1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:63,182,073...63,215,349
Ensembl chr11:63,182,349...63,213,942
|
|
G |
H2ac18 |
H2A clustered histone 18 |
increases expression |
ISO |
Haloperidol results in increased expression of H2AC18 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:183,808,398...183,808,992
|
|
G |
H2ac20 |
H2A clustered histone 20 |
increases expression |
ISO |
Haloperidol results in increased expression of H2AC20 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:183,779,879...183,780,357
|
|
G |
H2aj |
H2A.J histone |
increases expression |
ISO |
Haloperidol results in increased expression of H2AJ protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:169,675,718...169,676,202
Ensembl chr 4:169,675,752...169,677,006
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of HADHB protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hars1 |
histidyl-tRNA synthetase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of HARS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740
|
|
G |
Hcfc1 |
host cell factor C1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of HCFC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:151,687,779...151,712,688
Ensembl chr X:151,687,779...151,712,638
|
|
G |
Higd1a |
HIG1 hypoxia inducible domain family, member 1A |
increases expression |
ISO |
Haloperidol results in increased expression of HIGD1A mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:130,391,658...130,400,888
Ensembl chr 8:121,514,156...121,523,443
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases activity increases expression multiple interactions |
ISO |
Haloperidol results in increased activity of HMGCR protein Haloperidol results in increased expression of HMGCR mRNA [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Cholesterol; [Haloperidol results in increased activity of HMGCR protein] which results in increased abundance of Triglycerides |
CTD |
PMID:16027736 PMID:17052361 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of HMGCS1 mRNA |
CTD |
PMID:16027736 PMID:17052361 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of HNRNPC protein |
CTD |
PMID:34122009 |
|
NCBI chr15:24,779,593...24,809,213
Ensembl chr15:24,779,450...24,809,183
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression |
ISO |
Haloperidol results in decreased expression of HNRNPK protein |
CTD |
PMID:34122009 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions increases expression |
EXP |
Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA] |
CTD |
PMID:12464447 PMID:15860345 PMID:20147574 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hpcal4 |
hippocalcin-like 4 |
decreases expression |
EXP |
Haloperidol results in decreased expression of HPCAL4 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of HSD17B4 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hspg2 |
heparan sulfate proteoglycan 2 |
decreases expression multiple interactions |
ISO |
Haloperidol results in decreased expression of HSPG2 mRNA HSPG2 gene results in increased susceptibility to [Haloperidol co-treated with Reserpine] |
CTD |
PMID:20072119 |
|
NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:149,677,476...149,778,594
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of HSPH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Htr1d |
5-hydroxytryptamine receptor 1D |
decreases expression |
EXP |
Haloperidol results in decreased expression of HTR1D mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:148,656,252...148,676,532
Ensembl chr 5:148,674,495...148,675,619
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects binding multiple interactions |
EXP ISO |
Haloperidol binds to HTR2A protein [Phencyclidine co-treated with Haloperidol] affects the activity of HTR2A protein |
CTD |
PMID:7520908 PMID:12191584 PMID:15380371 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2c |
5-hydroxytryptamine receptor 2C |
decreases expression |
EXP |
Haloperidol results in decreased expression of HTR2C mRNA |
CTD |
PMID:17868938 |
|
NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of ID2 mRNA Haloperidol results in increased expression of ID2 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ikbip |
IKBKB interacting protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of IKBIP protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:25,579,865...25,598,548
Ensembl chr 7:25,579,832...25,605,162
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Cannabidiol co-treated with Haloperidol] results in increased expression of IL10 protein |
CTD |
PMID:30217539 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [Haloperidol results in increased expression of IL1B protein] |
CTD |
PMID:30217539 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Haloperidol results in increased expression of IL6 mRNA Cannabidiol inhibits the reaction [Haloperidol results in increased expression of IL6 mRNA] |
CTD |
PMID:30217539 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilkap |
ILK associated serine/threonine phosphatase |
decreases expression |
EXP |
Haloperidol results in decreased expression of ILKAP mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:91,966,440...91,988,791
Ensembl chr 9:91,966,441...91,988,892
|
|
G |
Impdh1 |
inosine monophosphate dehydrogenase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of IMPDH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:57,801,842...57,817,434
Ensembl chr 4:57,801,831...57,819,076
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of INHA mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Haloperidol results in increased expression of INHBE mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression decreases expression |
EXP |
Haloperidol results in increased expression of JUN mRNA; Haloperidol results in increased expression of JUN protein Haloperidol results in decreased expression of JUN mRNA |
CTD |
PMID:12093589 PMID:12125044 PMID:15860345 PMID:18208916 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of JUNB mRNA] Haloperidol results in decreased expression of JUNB mRNA |
CTD |
PMID:12093589 PMID:19695244 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcna1 |
potassium voltage-gated channel subfamily A member 1 |
increases expression |
ISO |
Haloperidol results in increased expression of KCNA1 mRNA; Haloperidol results in increased expression of KCNA1 protein |
CTD |
PMID:18797397 |
|
NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682
|
|
G |
Kcnab1 |
potassium voltage-gated channel subfamily A regulatory beta subunit 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KCNAB1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 2:149,137,025...149,603,540
Ensembl chr 2:149,137,041...149,603,534
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Haloperidol inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Haloperidol results in decreased activity of KCNH2 protein |
CTD |
PMID:15671647 PMID:16278312 PMID:16494862 PMID:19583963 PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnip3 |
potassium voltage-gated channel interacting protein 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KCNIP3 mRNA; Haloperidol results in decreased expression of KCNIP3 protein |
CTD |
PMID:18797397 |
|
NCBI chr 3:114,677,027...114,742,923
Ensembl chr 3:114,677,030...114,743,556
|
|
G |
Kdm1a |
lysine demethylase 1A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of KDM1A protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression |
ISO |
Haloperidol results in increased expression of KDR protein |
CTD |
PMID:34122009 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
Haloperidol results in decreased expression of KIF5C protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:54,441,266...54,591,630
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Kiz |
kizuna centrosomal protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of KIZ protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:134,277,631...134,385,260
Ensembl chr 3:134,277,687...134,385,190
|
|
G |
Klc1 |
kinesin light chain 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of KLC1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 6:136,644,592...136,690,399
Ensembl chr 6:130,823,419...130,867,031
|
|
G |
Klc4 |
kinesin light chain 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of KLC4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:21,834,765...21,848,676
Ensembl chr 9:14,337,534...14,351,066
|
|
G |
Klhdc2 |
kelch domain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of KLHDC2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:87,777,183...87,791,609
Ensembl chr 6:87,777,183...87,804,187
|
|
G |
Kmt2a |
lysine methyltransferase 2A |
decreases expression |
ISO |
Haloperidol results in decreased expression of KMT2A mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 8:45,116,763...45,193,320
Ensembl chr 8:45,118,814...45,193,181
|
|
G |
Kpna4 |
karyopherin subunit alpha 4 |
increases expression |
ISO |
Haloperidol results in increased expression of KPNA4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases expression |
EXP |
Haloperidol results in increased expression of KRAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:179,916,255...179,949,613
|
|
G |
Kremen1 |
kringle containing transmembrane protein 1 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of KREMEN1 protein Haloperidol results in increased expression of KREMEN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:80,081,870...80,147,489
Ensembl chr14:80,084,403...80,147,516
|
|
G |
Lamtor3 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 3 |
increases expression |
ISO |
Haloperidol results in increased expression of LAMTOR3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:226,411,389...226,423,612
Ensembl chr 2:226,411,400...226,423,607
|
|
G |
Ldhb |
lactate dehydrogenase B |
decreases expression increases expression |
ISO EXP |
Haloperidol results in decreased expression of LDHB mRNA Haloperidol results in increased expression of LDHB mRNA |
CTD |
PMID:15860345 PMID:16465460 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Haloperidol results in increased expression of LDLR mRNA |
CTD |
PMID:17052361 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of LGALS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lipa |
lipase A, lysosomal acid type |
increases expression |
ISO |
Haloperidol results in increased expression of LIPA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Mag |
myelin-associated glycoprotein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MAG mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 1:86,148,227...86,163,726
Ensembl chr 1:86,148,228...86,163,656
|
|
G |
Map1a |
microtubule-associated protein 1A |
increases expression decreases expression |
EXP ISO |
Haloperidol results in increased expression of MAP1A mRNA Haloperidol results in decreased expression of MAP1A protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr 3:128,716,907...128,736,638
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map2 |
microtubule-associated protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP2 mRNA |
CTD |
PMID:15079866 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAP2K1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
decreases expression increases expression |
EXP ISO |
Haloperidol results in decreased expression of MAP2K2 mRNA Haloperidol results in increased expression of MAP2K2 mRNA |
CTD |
PMID:14647396 PMID:15860345 |
|
NCBI chr 7:9,241,449...9,264,216
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:72,520,616...72,748,395
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP3K1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:45,081,889...45,150,555
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Map3k12 |
mitogen activated protein kinase kinase kinase 12 |
increases expression |
EXP |
Haloperidol results in increased expression of MAP3K12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:135,507,082...135,527,396
Ensembl chr 7:133,630,835...133,640,789
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation decreases expression multiple interactions |
ISO EXP |
Haloperidol results in increased phosphorylation of MAPK1 protein Haloperidol results in decreased expression of MAPK1 mRNA [potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12871586 PMID:15860345 PMID:28017790 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK14 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Haloperidol results in increased phosphorylation of MAPK3 protein [potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]]; SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12871586 PMID:28017790 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk6 |
mitogen-activated protein kinase 6 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:76,146,650...76,169,767
Ensembl chr 8:76,146,690...76,169,720
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
EXP |
Haloperidol results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:17092607 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
affects expression |
EXP |
Haloperidol affects the expression of MAPK9 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of MAPRE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:142,218,846...142,246,990
Ensembl chr 3:142,212,955...142,246,983
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
decreases expression |
EXP |
Haloperidol results in decreased expression of MAS1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mbp |
myelin basic protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MBP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mcam |
melanoma cell adhesion molecule |
increases expression |
ISO |
Haloperidol results in increased expression of MCAM protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571
|
|
G |
Mchr1 |
melanin-concentrating hormone receptor 1 |
affects binding |
ISO |
Haloperidol binds to MCHR1 protein |
CTD |
PMID:16983399 |
|
NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:112,761,554...112,764,032
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
decreases expression |
ISO |
Haloperidol results in decreased expression of MMP10 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mog |
myelin oligodendrocyte glycoprotein |
decreases expression |
ISO |
Haloperidol results in decreased expression of MOG mRNA |
CTD |
PMID:17177202 |
|
NCBI chr20:1,513,137...1,523,473
Ensembl chr20:1,513,239...1,523,474
|
|
G |
Mrps31 |
mitochondrial ribosomal protein S31 |
increases expression |
ISO |
Haloperidol results in increased expression of MRPS31 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654
|
|
G |
Myadm |
myeloid-associated differentiation marker |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of MYADM protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,864,180...65,874,701
Ensembl chr 1:65,864,173...65,874,035
|
|
G |
Myo5b |
myosin Vb |
decreases expression |
ISO |
Haloperidol results in decreased expression of MYO5B protein |
CTD |
PMID:34122009 |
|
NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745
|
|
G |
Nap1l3 |
nucleosome assembly protein 1-like 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of NAP1L3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:88,347,595...88,350,393
Ensembl chr X:88,347,598...88,350,393
|
|
G |
Ncan |
neurocan |
decreases expression |
ISO |
Haloperidol results in decreased expression of NCAN mRNA |
CTD |
PMID:18797397 |
|
NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,301,969...19,328,436
|
|
G |
Ncaph |
non-SMC condensin I complex, subunit H |
decreases expression |
ISO |
Haloperidol results in decreased expression of NCAPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:134,825,271...134,852,502
Ensembl chr 3:114,371,941...114,399,180
|
|
G |
Ncl |
nucleolin |
increases expression |
ISO |
Haloperidol results in increased expression of NCL mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 9:94,447,559...94,456,083
Ensembl chr 9:86,998,019...87,008,136
|
|
G |
Ndufv1 |
NADH:ubiquinone oxidoreductase core subunit V1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of NDUFV1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:201,300,365...201,305,461
Ensembl chr 1:201,299,985...201,305,466
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
decreases expression |
ISO |
Haloperidol results in decreased expression of NEDD4 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of NFKB1 protein |
CTD |
PMID:16500086 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Ngfr |
nerve growth factor receptor |
decreases expression |
EXP |
Haloperidol results in decreased expression of NGFR mRNA |
CTD |
PMID:16513140 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nifk |
nucleolar protein interacting with the FHA domain of MKI67 |
decreases expression |
ISO |
Haloperidol results in decreased expression of NIFK protein |
CTD |
PMID:34122009 |
|
NCBI chr13:29,393,303...29,403,387
Ensembl chr13:29,393,286...29,405,896
|
|
G |
Nop14 |
NOP14 nucleolar protein |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of NOP14 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:76,081,313...76,102,454
Ensembl chr14:76,080,793...76,102,453
|
|
G |
Nop53 |
NOP53 ribosome biogenesis factor |
increases expression |
ISO |
Haloperidol results in increased expression of NOP53 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:76,629,084...76,636,902
Ensembl chr 1:76,629,069...76,636,902
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
Cannabidiol inhibits the reaction [Haloperidol results in increased expression of NOS2 mRNA] |
CTD |
PMID:30217539 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
affects activity |
EXP |
Haloperidol affects the activity of NPPA protein modified form |
CTD |
PMID:1363893 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nptx2 |
neuronal pentraxin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of NPTX2 mRNA |
CTD |
PMID:18208916 |
|
NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345
|
|
G |
Npy |
neuropeptide Y |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol promotes the reaction [Amphetamine results in decreased expression of NPY protein] Haloperidol results in increased expression of NPY protein Haloperidol results in decreased expression of NPY mRNA |
CTD |
PMID:7644023 PMID:15985714 PMID:16516965 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of NQO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Haloperidol results in increased expression of NR0B2 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 5:151,063,160...151,066,475
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
increases expression |
EXP |
Haloperidol results in increased expression of NR1D1 mRNA |
CTD |
PMID:11564422 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
affects response to substance multiple interactions increases expression decreases expression |
ISO EXP |
NR4A1 affects the susceptibility to Haloperidol 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of NR4A1 mRNA] Haloperidol results in decreased expression of NR4A1 mRNA |
CTD |
PMID:10987852 PMID:11564422 PMID:14603264 PMID:19695244 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
increases expression |
EXP |
Haloperidol results in increased expression of NR4A3 mRNA |
CTD |
PMID:19695244 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrg1 |
neuregulin 1 |
increases expression |
EXP |
Haloperidol results in increased expression of NRG1 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr16:65,954,084...67,007,484
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
decreases expression |
EXP ISO |
Haloperidol results in decreased expression of NSF mRNA Haloperidol results in decreased expression of NSF protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nts |
neurotensin |
multiple interactions increases expression |
ISO EXP |
SLC6A3 protein promotes the reaction [Haloperidol results in increased expression of NTS mRNA] Haloperidol results in increased expression of NTS mRNA; Haloperidol results in increased expression of NTS protein 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of NTS mRNA]; Theophylline inhibits the reaction [Haloperidol results in increased expression of NTS mRNA] |
CTD |
PMID:10199625 PMID:11120399 PMID:11602683 PMID:12887421 PMID:14603264 PMID:14698760 More...
|
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Numbl |
NUMB-like, endocytic adaptor protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of NUMBL mRNA |
CTD |
PMID:18797397 |
|
NCBI chr 1:82,549,814...82,573,788
Ensembl chr 1:82,550,054...82,573,776
|
|
G |
Nup54 |
nucleoporin 54 |
decreases expression |
ISO |
Haloperidol results in decreased expression of NUP54 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,617,630...15,636,029
Ensembl chr14:15,617,679...15,636,028
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Haloperidol results in increased expression of NUPR1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of OAT protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Oprl1 |
opioid related nociceptin receptor 1 |
affects response to substance |
ISO |
OPRL1 affects the susceptibility to Haloperidol |
CTD |
PMID:16237164 |
|
NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] |
CTD |
PMID:20184921 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Osbpl8 |
oxysterol binding protein-like 8 |
increases expression |
ISO |
Haloperidol results in increased expression of OSBPL8 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:46,596,944...46,749,888
Ensembl chr 7:46,596,983...46,749,888
|
|
G |
Park7 |
Parkinsonism associated deglycase |
increases expression |
ISO |
Haloperidol results in increased expression of PARK7 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pcmt1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PCMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:2,111,756...2,160,354
Ensembl chr 1:2,111,763...2,159,201
|
|
G |
Pcsk1n |
proprotein convertase subtilisin/kexin type 1 inhibitor |
increases expression |
ISO |
Haloperidol results in increased expression of PCSK1N mRNA |
CTD |
PMID:14647396 |
|
NCBI chr X:14,580,036...14,583,478
Ensembl chr X:14,580,038...14,583,566
|
|
G |
Pde10a |
phosphodiesterase 10A |
increases expression |
EXP |
Haloperidol results in increased expression of PDE10A mRNA; Haloperidol results in increased expression of PDE10A protein |
CTD |
PMID:18222493 |
|
NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:51,770,132...52,216,563
|
|
G |
Pde1b |
phosphodiesterase 1B |
increases expression |
EXP ISO |
Haloperidol results in increased expression of PDE1B mRNA; Haloperidol results in increased expression of PDE1B protein |
CTD |
PMID:14647396 PMID:18222493 |
|
NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Pde4a |
phosphodiesterase 4A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PDE4A protein |
CTD |
PMID:20222156 |
|
NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961
|
|
G |
Pde5a |
phosphodiesterase 5A |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [potassium bromate results in increased activity of PDE5A protein] |
CTD |
PMID:37865952 |
|
NCBI chr 2:213,542,822...213,687,638
Ensembl chr 2:210,858,063...210,999,701
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PDLIM5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
EXP |
[1-aminocyclopentane-1,2,4-tricarboxylic acid co-treated with Haloperidol] results in increased expression of PDYN mRNA |
CTD |
PMID:17224239 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Pdzrn3 |
PDZ domain containing RING finger 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PDZRN3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:133,770,736...133,996,959
Ensembl chr 4:133,770,736...133,996,959
|
|
G |
Penk |
proenkephalin |
multiple interactions increases expression |
ISO EXP |
3,4-dicarboxyphenylglycine promotes the reaction [Haloperidol results in increased expression of PENK mRNA]; Docosahexaenoic Acids inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Tretinoin inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] Haloperidol results in increased expression of PENK mRNA; Haloperidol results in increased expression of PENK protein 1-aminocyclopentane-1,2,4-tricarboxylic acid inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 1-aminoindan-1,5-dicarboxylic acid inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 2-(2,3-dicarboxycyclopropyl)glycine promotes the reaction [Haloperidol results in increased expression of PENK mRNA]; 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Memantine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] |
CTD |
PMID:3838946 PMID:7637876 PMID:12373537 PMID:12727308 PMID:12834887 PMID:12887421 PMID:14603264 PMID:14642644 PMID:15215559 PMID:17224239 More...
|
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Per1 |
period circadian regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PER1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431
|
|
G |
Pfdn5 |
prefoldin subunit 5 |
increases expression |
ISO |
Haloperidol results in increased expression of PFDN5 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 7:133,451,778...133,456,516
Ensembl chr 7:133,451,453...133,456,516
|
|
G |
Pfkp |
phosphofructokinase, platelet |
increases expression multiple interactions |
EXP ISO |
Haloperidol results in increased expression of PFKP mRNA [Cuprizone co-treated with Haloperidol] results in increased expression of PFKP protein |
CTD |
PMID:15860345 PMID:34122009 |
|
NCBI chr17:63,729,743...63,794,026
Ensembl chr17:63,729,780...63,794,018
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PFN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of PGK1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Phactr1 |
phosphatase and actin regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PHACTR1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr17:21,560,364...22,040,166
Ensembl chr17:21,562,721...22,039,831
|
|
G |
Picalm |
phosphatidylinositol binding clathrin assembly protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of PICALM mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:144,056,415...144,138,045
Ensembl chr 1:144,056,721...144,137,557
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PIK3R3 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:129,701,229...129,772,583
|
|
G |
Pkib |
cAMP-dependent protein kinase inhibitor beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PKIB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr20:37,511,564...37,608,607
Ensembl chr20:36,905,340...37,062,187
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
EXP |
Haloperidol results in increased expression of PKM mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plp1 |
proteolipid protein 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PLP1 mRNA |
CTD |
PMID:17177202 PMID:18797397 |
|
NCBI chr X:100,184,039...100,201,035
Ensembl chr X:100,185,767...100,201,032
|
|
G |
Plpbp |
pyridoxal phosphate binding protein |
increases expression |
ISO |
Haloperidol results in increased expression of PLPBP protein |
CTD |
PMID:34122009 |
|
NCBI chr16:65,003,292...65,014,886
Ensembl chr16:65,002,223...65,014,886
|
|
G |
Pls3 |
plastin 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of PLS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Pmpca |
peptidase, mitochondrial processing subunit alpha |
increases expression |
ISO |
Haloperidol results in increased expression of PMPCA protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:29,605,823...29,614,936
Ensembl chr 3:9,207,717...9,216,844
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
increases expression |
ISO |
Haloperidol results in increased expression of PPA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[Cannabidiol co-treated with Haloperidol] results in increased expression of PPARGC1A protein |
CTD |
PMID:30217539 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppm1a |
protein phosphatase, Mg2+/Mn2+ dependent, 1A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPM1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:91,439,094...91,486,139
Ensembl chr 6:91,438,834...91,480,697
|
|
G |
Ppm1b |
protein phosphatase, Mg2+/Mn2+ dependent, 1B |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPM1B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:9,646,695...9,707,471
Ensembl chr 6:9,655,765...9,707,974
|
|
G |
Ppm1f |
protein phosphatase, Mg2+/Mn2+ dependent, 1F |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of PPM1F protein |
CTD |
PMID:34122009 |
|
NCBI chr11:84,064,422...84,094,410
Ensembl chr11:84,064,420...84,094,340
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1CB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1cc |
protein phosphatase 1 catalytic subunit gamma |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1CC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:34,383,072...34,400,553
Ensembl chr12:34,383,072...34,400,553
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of PPP1R14B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319 Ensembl chr12:204,163,299...204,167,319
|
|
G |
Ppp1r1a |
protein phosphatase 1, regulatory (inhibitor) subunit 1A |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:134,654,578...134,662,236
Ensembl chr 7:134,654,579...134,662,230
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases phosphorylation |
ISO |
Haloperidol results in increased phosphorylation of PPP1R1B protein |
CTD |
PMID:12871586 |
|
NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775
|
|
G |
Ppp1r2 |
protein phosphatase 1, regulatory (inhibitor) subunit 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr11:69,472,676...69,494,468
Ensembl chr11:69,472,555...69,494,463
|
|
G |
Ppp1r9b |
protein phosphatase 1, regulatory subunit 9B |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP1R9B protein |
CTD |
PMID:16844384 |
|
NCBI chr10:79,938,055...79,954,085
Ensembl chr10:79,938,066...79,954,083
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2CA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:36,856,534...36,878,789
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp2cb |
protein phosphatase 2 catalytic subunit beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2CB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
EXP |
Haloperidol results in increased expression of PPP2R1A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of PPP2R2A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions decreases expression |
EXP |
[Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein Haloperidol results in decreased expression of PPP3CA mRNA; Haloperidol results in decreased expression of PPP3CA protein |
CTD |
PMID:16033416 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression multiple interactions |
ISO |
Haloperidol results in decreased expression of PPP5C mRNA [Cuprizone co-treated with Haloperidol] results in decreased expression of PPP5C protein |
CTD |
PMID:14647396 PMID:34122009 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
increases expression |
EXP |
Haloperidol results in increased expression of PRKACA mRNA; Haloperidol results in increased expression of PRKACA protein |
CTD |
PMID:15860345 PMID:26894264 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
increases expression |
EXP |
Haloperidol results in increased expression of PRKACB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions increases expression |
EXP ISO |
Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2A protein] [Cuprizone co-treated with Haloperidol] results in decreased expression of PRKAR2A protein Haloperidol results in increased expression of PRKAR2A mRNA; Haloperidol results in increased expression of PRKAR2A protein |
CTD |
PMID:11907174 PMID:34122009 |
|
NCBI chr 8:118,271,608...118,337,332
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkar2b |
protein kinase cAMP-dependent type II regulatory subunit beta |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol promotes the reaction [Cyclic AMP binds to PRKAR2B protein] Haloperidol results in increased expression of PRKAR2B mRNA; Haloperidol results in increased expression of PRKAR2B protein Haloperidol results in decreased expression of PRKAR2B mRNA |
CTD |
PMID:11907174 PMID:15860345 |
|
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions increases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein Haloperidol results in increased expression of PRKCB mRNA |
CTD |
PMID:15860345 PMID:15967061 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkce |
protein kinase C, epsilon |
increases expression |
EXP |
Haloperidol results in increased expression of PRKCE mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prkcsh |
PRKCSH beta subunit of glucosidase II |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PRKCSH protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
|
|
G |
Prkcz |
protein kinase C, zeta |
increases expression |
EXP |
Haloperidol results in increased expression of PRKCZ mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prl |
prolactin |
affects expression increases secretion multiple interactions increases expression |
ISO EXP |
Haloperidol affects the expression of PRL protein Haloperidol results in increased secretion of PRL protein Haloperidol inhibits the reaction [Aripiprazole results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [talipexole results in decreased secretion of PRL protein]; LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)- inhibits the reaction [Haloperidol results in increased expression of PRL protein]; Triptorelin Pamoate inhibits the reaction [Haloperidol results in increased expression of PRL protein] |
CTD |
PMID:1304992 PMID:1380082 PMID:2136057 PMID:3019639 PMID:3158510 PMID:3883215 PMID:3906589 PMID:7018927 PMID:7214106 PMID:7348089 PMID:7670571 PMID:8613910 PMID:8915564 PMID:9090331 PMID:9128918 PMID:9265911 PMID:9265916 PMID:9376336 PMID:9572212 PMID:10661492 PMID:11048906 PMID:11071396 PMID:11997696 PMID:15289996 PMID:15638391 PMID:16282852 PMID:18521575 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prpf19 |
pre-mRNA processing factor 19 |
increases expression |
ISO |
Haloperidol results in increased expression of PRPF19 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:207,541,582...207,552,664
Ensembl chr 1:207,541,595...207,552,662
|
|
G |
Prpf38b |
pre-mRNA processing factor 38B |
decreases expression |
ISO |
Haloperidol results in decreased expression of PRPF38B mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 2:196,553,224...196,562,271
Ensembl chr 2:196,553,225...196,562,250
|
|
G |
Prrc2a |
proline-rich coiled-coil 2A |
decreases expression |
ISO |
Haloperidol results in decreased expression of PRRC2A mRNA |
CTD |
PMID:18797397 |
|
NCBI chr20:3,658,391...3,674,143
Ensembl chr20:3,658,695...3,674,130
|
|
G |
Prxl2a |
peroxiredoxin like 2A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PRXL2A protein |
CTD |
PMID:34122009 |
|
NCBI chr16:16,866,601...16,886,378
Ensembl chr16:16,866,603...16,886,433
|
|
G |
Psmb9 |
proteasome 20S subunit beta 9 |
decreases expression |
EXP |
Haloperidol results in decreased expression of PSMB9 mRNA |
CTD |
PMID:16452686 |
|
NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512
|
|
G |
Psmd12 |
proteasome 26S subunit, non-ATPase 12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PSMD12 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:92,438,223...92,457,323
Ensembl chr10:92,438,298...92,457,287
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Haloperidol results in increased expression of PTGS2 mRNA |
CTD |
PMID:30217539 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptma |
prothymosin alpha |
increases expression |
ISO |
Haloperidol results in increased expression of PTMA protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333
|
|
G |
Ptms |
parathymosin |
increases expression |
ISO |
Haloperidol results in increased expression of PTMS mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009
|
|
G |
Pura |
purine rich element binding protein A |
increases expression |
ISO |
Haloperidol results in increased expression of PURA protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,159,103...28,179,539
Ensembl chr18:27,884,556...27,905,513
|
|
G |
Purb |
purine rich element binding protein B |
decreases expression |
ISO |
Haloperidol results in decreased expression of PURB protein |
CTD |
PMID:34122009 |
|
NCBI chr14:81,342,374...81,344,857
Ensembl chr14:81,336,448...81,351,432
|
|
G |
Pvalb |
parvalbumin |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [Phencyclidine results in decreased expression of PVALB mRNA] |
CTD |
PMID:12589379 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Pycr1 |
pyrroline-5-carboxylate reductase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of PYCR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:105,917,732...105,922,658
Ensembl chr10:105,917,680...105,922,549
|
|
G |
Pygm |
glycogen phosphorylase, muscle associated |
decreases expression |
ISO |
Haloperidol results in decreased expression of PYGM protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:203,690,550...203,705,369
Ensembl chr 1:203,690,533...203,705,368
|
|
G |
Qki |
QKI, KH domain containing RNA binding |
increases expression |
ISO |
Haloperidol results in increased expression of QKI mRNA alternative form |
CTD |
PMID:19335891 |
|
NCBI chr 1:50,387,716...50,501,568
Ensembl chr 1:50,387,698...50,498,831
|
|
G |
Rab10 |
RAB10, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB10 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:26,267,081...26,319,739
Ensembl chr 6:26,266,859...26,320,193
|
|
G |
Rab11a |
RAB11a, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB11A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:65,223,698...65,246,461
Ensembl chr 8:65,222,949...65,246,525
|
|
G |
Rab12 |
RAB12, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB12 mRNA |
CTD |
PMID:12437575 |
|
NCBI chr 9:106,480,301...106,506,895
Ensembl chr 9:106,480,301...106,506,910
|
|
G |
Rab28 |
RAB28, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB28 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:69,245,846...69,322,968
Ensembl chr14:69,245,854...69,322,967
|
|
G |
Rab4a |
RAB4A, member RAS oncogene family |
decreases expression |
EXP |
Haloperidol results in decreased expression of RAB4A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr19:51,795,613...51,822,706
Ensembl chr19:51,795,613...51,822,703
|
|
G |
Rab5a |
RAB5A, member RAS oncogene family |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of RAB5A protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:6,483,906...6,512,877
Ensembl chr 9:6,484,469...6,512,873
|
|
G |
Rab6a |
RAB6A, member RAS oncogene family |
increases expression |
EXP |
Haloperidol results in increased expression of RAB6A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715
|
|
|